Seroprevalence of antibody to influenza A(H1N1)pdm09 attributed to vaccination or infection, before and after the second (2010) pandemic wave in Australia

Influenza and other Respiratory Viruses

Volumn 8, Issue 2, 2014, Pages 194-200

  Mcvernon, Jodie ^a,b   Laurie, Karen ^c   Faddy, Helen ^d   Irving, David ^d   Nolan, Terry ^a   Barr, Ian ^c   Kelso, Anne ^c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^c WHO COLLABORATING CENTRE FOR REFERENCE AND RESEARCH ON INFLUENZA   (Australia)

^d AUSTRALIAN RED CROSS BLOOD SERVICE   (Australia)

Author keywords

Blood donors; Immunity, herd; Influenza, human; Pandemics; Serology; Vaccination

Indexed keywords

BLOOD DONORS; IMMUNITY, HERD; INFLUENZA, HUMAN; PANDEMICS; SEROLOGY; VACCINATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; AUSTRALIA; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; SEROEPIDEMIOLOGIC STUDIES; YOUNG ADULT;

EID: 84894489410     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/irv.12225     Document Type: Article

References (27)

1. Mathews JD, Chesson JM, McCaw JM, McVernon J. Understanding influenza transmission, immunity and pandemic threats. Influenza Other Respir Viruses 2009; 3:143-149.
2. Fleming DM, Elliot AJ. Lessons from 40 years' surveillance of influenza in England and Wales. Epidemiol Infect 2008; 136:866-875.
3. Leung G, Nicoll A. Reflections on pandemic (H1N1) 2009 and the International response. PLoS Med 2010; 7:e1000346.
4. Brien S, Kwong JC, Buckeridge DL. The determinants of 2009 pandemic A/H1N1 influenza vaccination: a systematic review. Vaccine [Research Support, Non-U.S. Gov't Review] 2012; 30:1255-1264.
5. Bishop JF, Murnane MP, Owen R. Australia's winter with the 2009 pandemic influenza A (H1N1) virus. N Engl J Med 2009; 361:2591-2594.
6. Australian Government Department of Health and Ageing. Review of Australia's Health Sector Response to Pandemic (H1N1) 2009. Lessons Identified. Canberra: Australian Government Department of Health and Ageing, 2011.
7. Hoschler K, Thompson C, Andrews N et al. Seroprevalence of influenza A(H1N1)pdm09 virus antibody, England, 2010 and 2011. Emerg Infect Dis 2012; 18:1894-1897.
8. Yang P, Zhang L, Shi W et al. Seroprevalence of pandemic (H1N1) 2009 influenza and effectiveness of 2010/2011 influenza vaccine during 2010/2011 season in Beijing, China. Influenza Other Respir Viruses [Research Support, Non-U.S. Gov't] 2012; 6:381-388.
9. Yang F, He J, Zhong H et al. Temporal trends of influenza A (H1N1) virus seroprevalence following 2009 pandemic wave in Guangdong, China: three cross-sectional serology surveys. PLoS ONE [Research Support, Non-U.S. Gov't] 2012; 7:e38768.
10. Ross T, Zimmer S, Burke D et al. Seroprevalence following the second wave of pandemic 2009 H1N1 influenza. PLoS Curr 2010; 2:RRN1148.
11. Adamson WE, McGregor EC, Kavanagh K et al. Population exposure to a novel influenza A virus over three waves of infection. J Clin Virol [Research Support, Non-U.S. Gov't] 2011; 52:300-303.
12. Morner A, Brave A, Kling AM et al. Pandemic influenza A(H1N1)pdm09 seroprevalence in Sweden before and after the pandemic and the vaccination campaign in 2009. PLoS ONE [Research Support, Non-U.S. Gov't] 2012; 7:e53511.
13. McVernon J, Laurie K, Nolan T et al. Seroprevalence of 2009 pandemic influenza A(H1N1) virus in Australian blood donors, October - December 2009. Euro Surveill 2010; 15:pii:19678.
14. Australian influenza surveillance summary report. 2010;44:30 October - 5 November.
15. WHO Collaborating Centres for Reference and Research on Influenza. Concepts and Procedures for Laboratory-Based Influenza Surveillance. Washington, DC: US Department of Health and Human Services, 1982.
16. Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med Bull 1979; 35:69-75.
17. Australian Government Australian Institute for Health and Welfare. 2009 Adult Vaccination Survey. Provisional Topline Results for H1N1 Vaccination Uptake. Canberra: Australian Government Australian Institute for Health and Welfare, 2010.
18. Australian influenza surveillance report. Number 44, 2010, Reporting Period 30 October-5 November. Australian Government Department of Health and Ageing, 2010.
19. Wood JM, Gaines-Das RE, Taylor J, Chakraverty P. Comparison of influenza serological techniques by international collaborative study. Vaccine 1994; 12:167-174.
20. Petrie JG, Ohmit SE, Johnson E, Cross RT, Monto AS. Efficacy studies of influenza vaccines: effect of end points used and characteristics of vaccine failures. J Infect Dis [Research Support, N.I.H., Extramural] 2011; 203:1309-1315.
21. Weekly report. Chinese National Influenza Centre, 2011;Week 29(August 1).
22. Zhu FC, Wang H, Fang HH et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009; 361:2414-2423.
23. Cramer J, Mac T, Hogan B et al. Influenza A(H1N1)pdm09 antibodies after pandemic and trivalent seasonal influenza vaccination as well as natural infection in November 2010 in Hamburg, Germany. Euro Surveill 2012; 17:pii:20052.
24. Greer AL, Tuite A, Fisman DN. Age, influenza pandemics and disease dynamics. Epidemiol Infect 2010; 138:1542-1549.
25. Katriel G. Note on 'Age, influenza pandemics and disease dynamics' by Greer et al. (2010). Epidemiol Infect [Comment Letter Research Support, Non-U.S. Gov't] 2011; 139:1440-1441; author reply 1-2.
26. Van Kerkhove MD, Hirve S, Koukounari A, Mounts AW. Estimating age-specific cumulative incidence for the 2009 influenza pandemic: a meta-analysis of A(H1N1)pdm09 serological studies from 19 countries. Influenza Other Respir Viruses 2013; 7:872-886.
27. Laurie KL, Huston P, Riley S et al. Influenza serological studies to inform public health action: best practices to optimise timing, quality and reporting. Influenza Other Respir Viruses 2013; 7:211-224.